Latest News and Press Releases
Want to stay updated on the latest news?
-
Alumis Announces Proposed Public Offering of Common Stock
-
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
-
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
-
Alumis reports third quarter 2025 financial results and highlights recent progress and anticipated milestones including Phase 3 data in early 1Q 2026
-
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update